Chamomile

Chamomile is one of the most familiar and commercially understood botanical ingredients across EU and US markets. Derived from the dried flower heads of Matricaria chamomilla, it has been used in traditional herbal preparations for centuries. In modern nutraceutical manufacturing, chamomile is valued for its pleasant floral taste, low cost, and compatibility with gummy and sachet formats.

Brands use chamomile in private-label gummy ranges to tap into the growing demand for natural relaxation and sleep-support products. Its mild flavour profile makes it easy to formulate into palatable gummies, and its established consumer recognition reduces the need for extensive education. While chamomile itself carries no authorised EU health claims, it is frequently co-formulated with nutrients such as Magnesium or Vitamin B6 to support nervous-system function claims.

Origin and history

Chamomile has been used in traditional medicine across Europe, the Middle East, and North Africa for over 2,000 years. The ancient Egyptians dedicated chamomile to their sun god Ra, while Greek and Roman physicians prescribed it for various ailments. European herbalists have documented its use in calming preparations since the Middle Ages.

Industrial production of chamomile extract for dietary supplements began in the mid-20th century. Today, the majority of commercial chamomile is cultivated in Egypt, Hungary, Germany, and Argentina. The flowers are harvested, dried, and processed into standardised extracts or powdered forms suitable for gummy and sachet manufacturing. Standardisation to apigenin content ensures batch-to-batch consistency for commercial applications.

Scientific overview

Chamomile contains several bioactive compounds, with apigenin being the most studied marker. Apigenin is a flavonoid that binds to benzodiazepine receptors in the central nervous system, contributing to its calming effects. Other compounds include bisabolol, chamazulene, and luteolin, which contribute to the overall profile of the botanical.

Bioavailability of chamomile compounds varies by form. Standardised extracts with known apigenin content provide more predictable effects than whole-flower powders. The water-soluble nature of many chamomile constituents makes it suitable for gummy formulations, though extraction method and particle size affect final product consistency.

Manufacturing watchpoints include heat stability during gummy production — chamomile is heat-stable and soluble in gummy matrices, making it one of the easier botanicals to work with. Cost-per-mg is low compared to other botanical ingredients, and the pleasant floral taste requires minimal masking. Standardised extracts are preferred for commercial applications to ensure consistent active marker levels across batches.

Chamomile occupies a strong position in the relaxation and sleep-support category. It is one of the most recognised botanical ingredients globally, with high consumer trust and familiarity. Brands use it to create evening-focused products, bedtime gummy ranges, and stress-management formulations. The ingredient pairs naturally with other calming botanicals like Lemon Balm and with nutrients like Melatonin for sleep-specific positioning.

From a formulation and manufacturing perspective, chamomile is one of the most straightforward botanicals to incorporate into gummies. It is heat-stable, soluble, and has a pleasant taste that requires minimal masking. The low cost tier makes it accessible for entry-level private-label ranges, while standardised extracts allow for consistent dosing. DAT confirms final formulation parameters per project based on the selected extract form and target dosage.

For pack copy, brands should avoid disease claims and the term "anti-inflammatory" in EU markets. Chamomile has no authorised EFSA health claims under Reg. (EU) 432/2012 as it is on the on-hold list for botanicals. Positioning should focus on traditional use, relaxation, or sleep support without making specific health claims. Claim coverage can be supported by co-formulated nutrients with authorised claims. DAT reviews compliance per project and confirms certification status per batch before final label claims.